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Abstract
Background: Patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolysis are increasingly, and
ever earlier, referred for routine coronary angiography and where feasible, undergo percutaneous coronary
intervention (PCI). We sought to examine the randomized clinical trials (RCTs) on which this approach is based.
Methods: We systematically searched EMBASE, Medline, and references of relevant studies. All contemporary RCTs
(published since 1995) that compared systematic invasive management of STEMI patients after fibrinolysis with
standard care were included. Relevant study design and clinical outcome data were extracted.
Results: Nine RCTs that randomized a total of 3320 patients were identified. All suggested a benefit from routine
early invasive management. They were individually reviewed but important design variations precluded a formal
quantitative meta-analysis. Importantly, several trials did not compare a routine practice of invasive management
after fibrinolysis with a more selective ‘ischemia-guided’ approach but rather compared an early versus later routine
invasive strategy. In the other studies, recourse to subsequent invasive management in the usual care group varied
widely. Comparison of the effectiveness of a routine invasive approach to usual care was also limited by
asymmetric use of a second anti-platelet agent, differing enzyme definitions of reinfarction occurring
spontaneously versus as a complication of PCI, a preponderance of the ‘soft’ outcome of recurrent ischemia in the
combined primary endpoint, and an interpretative bias when invasive procedures on follow-up were tallied as an
endpoint without considering initial invasive procedures performed in the routine invasive arm.
Conclusions: Due to important methodological limitations, definitive RCT evidence in favor of routine invasive
management following fibrinolysis in patients with STEMI is presently lacking.
Background
The Case
A 66-year-old man presented at 4 AM at a community
hospital with chest pain of 90 min duration. His vital
signs were stable. The ECG showed ST-segment eleva-
tion of 3-5 mm in inferior leads and precordial leads
V5-V6 and ST-segment depression of 3-4 mm in leads
V1-V3. He received aspirin, clopidogrel, intravenous
morphine and bolus fibrinolytic therapy 2 h after the
start of his symptoms followed by low molecular weight
heparin. Over the next hour, the pain subsided signifi-
cantly and an ECG showed over 50% resolution of
ST-elevation. He was awakened at 8 AM for an ECG
that showed Q-waves and 1 mm ST-elevation and
T-wave inversion in inferior leads and T-wave inversion
only in V5-V6. Should the patient be transferred to the
nearest tertiary cardiac center 550 km away for cardiac
catheterization and revascularization or progressively
mobilized and risk stratified with an ECG stress test a
few days later?
The Case Revisited
The treating clinicians believed the patient should be
transferred to the tertiary cardiac center for coronary
angiography and revascularization if feasible. However,
it was Friday past noon and a snowstorm had developed
that was sustained over the weekend. The patient
continued to do well and was ambulatory Sunday. On
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satisfactory exercise test could obviate the need for inva-
sive management. The patient performed well on this
test and was discharged on aspirin, a statin and a beta-
blocker plus clopidogrel for 3 months. His life was
uneventful a year later.
Fibrinolysis remains a cornerstone for the treatment of
ST elevation myocardial infarction (STEMI) when pri-
mary percutaneous coronary intervention (PCI) is not
readily available. However, important clinical questions
arise with fibrinolysis. Should a ‘pharmacoinvasive
approach’, that is, fibrinolysis followed by routine coron-
ary angiography with PCI when anatomically feasible, be
performed in patients with STEMI or is an equivalent
clinical benefit achieved with a selective, ischemia-
guided approach to coronary angiography and revascu-
larization? And if a pharmacoinvasive approach is super-
ior, when after fibrinolysis should patients undergo
invasive intervention? And is the magnitude of benefit
compelling enough to justify systematic recourse to the
limited and costly resources of tertiary cardiac care?
Older studies (≥ 15 years ago) showed no benefit of
systematic invasive cardiac management of patient with
STEMI after fibrinolysis[1-3]. However, these studies are
no longer considered relevant in the ‘modern era’
because of the increasing sophistication of invasive tech-
nology with generalized use of stents, platelet 2b/3a gly-
coprotein antagonists and thienopyridines (such as
clopidogrel)[4,5]. North American guidelines have
tended towards a progressive acceptance of routine PCI
as part of an invasive strategy after fibrinolytic therapy
[6-8]. An even stronger endorsement of the pharma-
coinvasive strategy comes from the most recent Eur-
opean guidelines[9] that recommend, even in the case of
successful fibrinolysis, coronary angiography within 3-24
hours. Thus, the pharmacoinvasive approach is increas-
ingly becoming the norm. This evolution in clinical
practice and in expert opinion and its shades of differ-
ences based on a similar body of knowledge has
prompted us to perform a systematic review of the evi-
dence from randomized clinical trials (RCTs) examining
this issue.
Methods
This review was performed in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses, or PRISMA statement[10].
Data sources
We systematically searched EMBASE and Medline to
identify all RCTs published in English that compared
systematic invasive management of STEMI patients after
fibrinolysis with prevailing ‘standard’ or ‘usual care’.A
detailed description of our literature search strategy,
conducted in June 2010, and corresponding key words
is found in Additional file 1. Briefly, we combined
keyword searches for PCI or cardiac catheterization,
fibrinolysis or thrombolysis, STEMI or myocardial
infarction, and trials. We then restricted our search to
clinical trials, human subjects, and English language
publications. We also hand-searched references of
relevant publications for additional trials.
Study selection
We included RCTs that compared fibrinolysis followed
by standard or usual care with fibrinolysis plus routine
invasive management, performed at any time following
fibrinolysis. We included studies that differed only in
the timing of invasive management after fibrinolysis
because later invasive management was their standard
of care and because these studies have been invoked in
support of a routine pharmacoinvasive approach. We
excluded ‘rescue PCI’ studies (where emergency PCI
was performed because fibrinolysis was assessed to
have failed)[11-13] and ‘facilitated PCI’ studies (where
emergency PCI was considered part of the original
fibrinolytic strategy and where the comparator was
primary PCI)[14,15]. In addition, we excluded 12 trials
published ≥ 15 years ago as they have been critiqued
i nt h em o r ec o n t e m p o r a r ye r ao nt h eg r o u n d st h a t
they are no longer relevant because of advances in
cardiac percutaneous technology and adjuvant drug
treatment[4,5].
Data extraction
We extracted data regarding study design, including
sample size, duration of follow-up, and use of angiogra-
phy, PCI, and clopidogrel (or ticlopidine) in each
treatment group, and clinical outcomes at 30 days, 6
months, and 1 year. Where necessary, relative risks, 95%
confidence intervals (CI), and p-values were calculated
from presented count data. Data were extracted in
duplicate, with disagreements resolved by consensus.
Data synthesis
The disparate protocols and heterogeneous comparative
groups of the included trials precluded a formal meta-
analysis. The limited available data also prevented the
exploration of sources of heterogeneity via meta-analytic
tools such as meta-regression. We have therefore opted
to systematically review each individual trial.
Results
Out literature search identified 3,788 potentially relevant
publications (Figure 1). Of these publications, 64 were
retrieved for full text inspection. A total of 54 articles
were excluded upon closer inspection, including 12 trials
published ≥ 15 years ago. Consequently, 10 relevant
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These trials randomized a total of 3320 patients.
The characteristics of the trials examined and their
outcomes are summarized in Tables 1, 2, 3. We have
also created forest plots that sum up the individual out-
comes of the trials at 30 days and when available at 6
months and one year (Figures 2, 3, 4). An additional for-
est plot was created to summarize two 30-day composite
endpoints (death/reinfarction and death/reinfarction/
s t r o k e )t h a tw e r er e p o r t e d by three RCTs (Figure 5).
Due to the inconsistent reporting of other composite
endpoints, it was not practical to present these data
graphically. Instead, we summarize these data as part of
Tables 2 and 3. The pertinent points of the individual
studies are reviewed below.
PRAGUE Study
In this trial, 99 patients with STEMI were randomized
in non-PCI hospitals to streptokinase alone and 100
patients were randomized to streptokinase followed by
systematic transfer for immediate PCI[16]. Revasculariza-
tion was performed within 30 days in 14% (including res-
cue PCI in 7%) of the streptokinase alone group. The
occurrences of death, reinfarction, and stroke at 30 days
were 14%, 10%, and 1%, respectively, in the streptokinase
alone group versus 12%, 7%, and 3%, respectively, in the
streptokinase plus immediate PCI group. The relative
risk for the occurrence of the composite endpoint of
death, reinfarction, and stroke in favor of the latter group
was 0.65 (95% CI: 0.36-1.16, p = 0.14). The authors later
reported outcomes at one year[17]. The composite end-
point of death, reinfarction, and stroke was not reported
at one year. Rather the endpoint of death and reinfarction
was reported as 30% in the streptokinase alone group
versus 18% in the pharmacoinvasive group (relative risk
0.59; 95% CI: 0.36-0.99; p = 0.04). Limitations of this
s t u d ya r et h eu s eo faf i b r i n o l y tic strategy generally con-
sidered to be inferior, the relatively small number of
patients, and the lack of consistency in reporting the
same endpoint at the 2 points in time.
SIAM-3
In this study, 197 STEMI patients were treated with
reteplase and randomized to 1 of 2 approaches: immedi-
ate stenting (median time, 3.5 hours) or elective stenting
after 2 weeks[18]. Thirty-four patients were excluded
after randomization because of the need for bypass sur-
gery or the presence of a non-significant or unapparent
infarct-related culprit lesion. Immediate stenting
resulted in a reduction in the primary 6-month compo-
site endpoint of death, reinfarction, target lesion revas-
cularization, and recurrent ischemic events (25.6%
versus 50.6%; relative risk 0.51; 95% CI: 0.33-0.78; p =
0.001). The difference between the 2 groups was driven
by ischemic events (4.9% vs. 28.4%, relative risk 0.17;
95% CI: 0.06-0.47; p = 0.001), more than by death or
reinfarction (7.3% vs. 13.6%; relative risk 0.54; 95% CI;
0.21-1.39; p = 0.146). Furthermore, this relatively small
study did not examine the role of a selective invasive
approach as all patients received the invasive interven-
tion, merely at 2 different times (3.5 hours versus 2
weeks). The pertinence of tallying ischemic events that
occurred after 2 weeks and out to 6 months (at least
50% by visual inspection of the Kaplan Meier survival
analysis) is intuitively unclear since by 2 weeks both
arms had received the same treatment. The large exclu-
sion of patients following randomization is also a threat
to the internal validity of the study, as is the unac-
counted role of differential exposure to clopidogrel
between the two groups (given within a few hours in
one group but 2 weeks later in the other group).
GRACIA-1
The GRACIA-1 study randomized 500 STEMI patients
to a routine invasive strategy within 24 hours of fibrino-
lysis or to an ischemia-guided ‘conservative’ approach
[19]. The hypothesis of this study was well formulated,
its design clear, and its sample size relatively robust.
Coronary angiography was performed at a median of 17
hours after fibrinolysis in the invasive group. In-hospital
coronary angiography was performed in 21% of the
ischemia-guided group. Criteria for recourse to coronary
angiography and revascularization in the ischemia-
guided group were clearly defined (spontaneous
Figure 1 Flow diagram of literature search of relevant
randomized clinical trials (RCTs).
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non-invasive stress testing of a severe ischemic sub-
strate). Thus, in this study, there was a clear distinction
between the 2 clinical approaches conducive for a mean-
ingful comparison. Revascularization (with stenting in
over 95% of patients) was performed in 83% of the inva-
sive group compared with 20% of the ischemia-guided
group. It was not specified whether any rescue PCI was
performed. The primary combined endpoint of death,
reinfarction, and revascularization at 12 months
occurred in 21% of the ischemia-guided group versus
9 %o ft h ei n v a s i v eg r o u p( r e l a t i v er i s k :0 . 4 4 ,9 5 %C I :
0.28-0.70; p = 0.0008). This difference was essentially
driven by differences in revascularization procedures
between groups. However, the inclusion of this compo-
nent of the composite endpoint is problematic as it
involves the actual intervention in only one group.
Thus, the inference that this study supports the use of a
systematic invasive approach following fibrinolysis is
valid if one accepts the authors’ position of not counting
the initial 208 in-hospital revascularizations performed
in the invasive group. If these initial procedures are
counted in the 12-month total of revascularization pro-
cedures, an entirely different conclusion is drawn, with
Table 1 Study characteristics of randomized clinical trials comparing an invasive treatment strategy to a delayed
invasive or ischemia-guided approach among STEMI patients treated with fibrinolysis
Study Year Sample
Size
Comparator Angiogram
in Invasive
Group (%)
Angiogram
in Selective
Group (%)
PCI in
Invasive
Group
(%)
PCI in
Selective
Group
(%)
Clopidogrel
Use in
Invasive
Group (%)
Clopidogrel
Use in
Selective
Group (%)
Follow-
Up
(Month)
PRAGUE
[16,17]
2000 300* Streptokinase NR NR 82
† 7
† All received ticlopidine 1
SIAM-3[18] 2003 197
‡ Reteplase with elective
stenting 2 weeks post-
thrombolysis
100 100 100 100 100 100
# 9.4 ±
7.4
GRACIA-1
[19]
2004 500 Recombinant tissue
plasminogen activator
with ischemia-guided
approach
100 21 81.4
¥ 20.3 NR NR 12
CAPITAL-
AMI[20]
2005 170 TNK-alone with rescue
PCI PRN
100 67 100 50 91 57 6
Leipzig[23] 2005 164 Combination half-dose
reteplase and abciximab
with rescue PCI PRN
and elective PCI
recommended before
hospital discharge
100 NR 96 91 88 77
## 6
WEST[25] 2006 304
€ TNK followed by ‘usual
standard of care’
98.1 NR 78.8
£ 60 NR NR 1
CARESS-AMI
[26]
2008 600 Combination half-dose
reteplase and abciximab
with transfer for rescue
PCI PRN
††
97.0 35.7 85.6 30.3 85.9** 57.1** 1
TRANSFER
AMI[27]
2009 1,059 TNK with rescue PCI
PRN and recommended
angiogram within 2
weeks of Index MI
98.5 89 85 67 89
†† 69
†† 6
NORDISTEMI
[28]
2009 266
‡‡ TNK with ischemia-
guided approach
99
¥¥ 95
¥¥ 89 71 100 12
Abbreviations: MI: myocardial infarction; PCI: percutaneous coronary intervention; PRN: as needed; STEMI: ST-elevation myocardial infarction; TNK: tenecteplase.
*Of the 300 patients randomized in PRAGUE, 101 were randomized to primary PCI and are not included in this analysis. A total of 100 patients were randomized
to streptokinase + PCI and 99 were randomized to streptokinase alone.
†These data represent procedures that occurred within the index hospitalization; 5
patients in the invasive group and 11 patients (including 7 rescue PCI) in the conservative group underwent PCI in the 30 days following randomization.
‡In the
SIAM-3 trial, 197 patients were initially randomized. However, only 163 met their secondary inclusion criteria. The remaining 34 patients were excluded. Data
presented here are based on the 163 patients who met the secondary inclusion criteria.
#Although all patients in the SIAM study received clopidogrel, patients
randomized to the delayed invasive approach received clopidogrel 2 weeks later than those randomized to an early invasive approach.
¥Includes 199 patients
who underwent stenting of culprit lesion and 3 who underwent stenting of non-culprit lesions.
€In the WEST study, 304 patients were randomized to 3 treatment
arms. However, only 2 of these arms are considered here (n = 204).
##Most patients in the selective group received clopidogrel at the time of PCI several days
after the index event.
£Includes 1 patient revascularized after index hospitalization but within 30 days of the index event. **Denotes clopidogrel use at discharge.
††Denotes clopidogrel use before admission or within the first 6 hours.
‡‡A total of 266 patients were randomized. However, 4/138 randomized to immediate
transfer for PCI and 6/138 randomized to the ischemia-guided approach were excluded following randomization. Consequently, all analyses are based on 134
and 132 patients, respectively.
¥¥ In the early invasive group, 83% underwent angiography within 3 hours of TNK and 99% with 12 hours. In the selective group,
12% underwent angiography with 3 hours, 33% within 12 hours, and 86% within 30 days.
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invasive or ischemia-guided approach among STEMI patients treated with fibrinolysis
Study Outcome Risk in Invasive
Group
(n/N)
Risk in Selective
Group
(n/N)
Relative Risk
(95% CI)
p-value
PRAGUE[16] Death/Reinfarction/Stroke* 15/100 23/99 0.65 (0.36, 1.16) 0.14
‡
Death 12/100 14/99 0.85 (0.41, 1.74) 0.66
‡
Reinfarction 7/100 10/99 0.69 (0.27, 1.75) 0.43
‡
Stroke 3/100 1/99 2.97 (0.31, 28.1) 0.62
‡
SIAM-3[18]
† CABG 0/82 0/81 - 1.00
TLR 2/82 2/81 0.99 (0.14, 6.84)
‡ 0.685
Ischemic Events 3/82 20/81 0.15 (0.05, 0.48)
‡ 0.01
Reinfarction 2/82 2/81 0.99 (0.14, 6.84)
‡ 0.685
Death 4/82 8/81 0.49 (0.15, 1.58)
‡ 0.179
Death/Reinfarction 6/82 10/81 0.59 (0.23, 1.55)
‡ 0.208
Death/Reinfarction/TLR 6/82 11/81 0.54 (0.21, 1.39)
‡ 0.146
Death/Reinfarction/TLR/Ischemic Events 7/82 25/81 0.28 (0.13, 0.60)
‡ 0.001
GRACIA-1[19] Death 6/248 6/251 1.01 (0.33, 3.10) 0.84
Non-Fatal Reinfarction 3/248 4/251 0.76 (0.17, 3.36) 0.98
Death/Non-Fatal Reinfarction 9/248 9/251 1.01 (0.41, 2.51) 0.97
Death/Non-Fatal Reinfarction/Revascularization 12/248 16/251 0.76 (0.37, 1.57) 0.46
CAPITAL-AMI[20] Death/Recurrent MI/Recurrent Unstable Ischemia,
Stroke
8/86 18/84 0.43 (0.20, 0.93) 0.03
Death 2/86 3/84 0.64 (0.11, 3.75) 0.68
Reinfarction 4/86 11/84 0.35 (0.12, 1.06) 0.06
Recurrent Unstable Ischemia 6/86 15/84 0.39 (0.16, 0.95) 0.04
Stroke 1/86 1/84 0.97 (0.61, 15.18) 1.00
Death/Reinfarction/Stroke 6/86 14/84 0.41 (0.17, 1.03) 0.06
Leipzig[23] Death 2/82 4/82 0.50 (0.09, 2.65)
‡ 0.68
‡
Non-Fatal Reinfarction 3/82 7/82 0.43 (0.11, 1.60)
‡ 0.33
‡
Stroke 0/82 1/82 - 1.00
‡
Major bleeding 4/82 5/82 0.80 (0.22, 2.87)
‡ 1.00
‡
Death/Reinfarction/Stroke/Major Bleeding 9/82 17/82 0.52 (0.23, 1.18) 0.13
¥
WEST[25] Death/Reinfarction/Refractory Ischemia/CHF/
Cardiogenic
Shock/Major Ventricular Arrhythmia*
25/104 25/100 0.96 (0.59, 1.56)
‡ 0.87
‡
Death 1/104 4/100 0.24 (0.03, 2.11)
‡ 0.21
‡
Reinfarction 6/104 9/100 0.64 (0.24, 1.74)
‡ 0.38
‡
CHF 15/104 15/100 0.96 (0.50, 1.86)
‡ 0.91
‡
Cardiogenic Shock 4/104 6/100 0.64 (0.19, 2.20)
‡ 0.53
‡
Refractory Ischemia 3/104 0/100 - 0.25
‡
Major Ventricular Arrhythmias 1/104 1/100 0.96 (0.06, 15.2)
‡ 1.00
‡
CARESS-AMI[26] Death/Reinfarction/Refractory Ischemia* 13/297 32/300 0.41 (0.22, 0.77)
‡ 0.005
Death 9/297 14/300 0.65 (0.29, 1.48)
‡ 0.40
Reinfarction 4/297 6/300 0.67 (0.19, 2.36)
‡ 0.75
Refractory Ischemia 1/297 12/300 0.08 (0.01, 0.64)
‡ 0.003
TRANSFER AMI
[27]
Death/Reinfarction/Recurrent Ischemia/New or
Worsening CHF/Cardiogenic Shock*
59/536 90/522 0.64 (0.47, 0.87) 0.004
Death 24/536 18/522 1.30 (0.71, 2.36) 0.39
Reinfarction 18/536 30/522 0.57 (0.33, 1.04) 0.06
Death/Reinfarction 38/536 47/522 0.79 (0.52, 1.19) 0.25
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in the invasive group compared with the ischemia-
guided group. The unbalanced use of clopidogrel is
again a confounding variable in this study. Although it
is unspecified, it can be assumed that nearly all patients
in the invasive group were treated for some time with
clopidogrel (or ticlopidine) while it is likely that few
patients in the ischemia-guided group received this
treatment prior to any revascularization procedure. As
well, there was a lower enzyme threshold (3 times the
normal value of creatine kinase MB isoenzyme) for
defining reinfarction within 48 h of fibrinolysis com-
pared with the definition of reinfarction within 48 h of
invasive intervention (5 times the normal value), which
may bias results against the conservative strategy.
Nevertheless, there was no statistically significant differ-
ence at one year in death or re-infarction between the 2
groups arms (risk ratio: 0.59; 95% CI: 0.33-1.05; p =
0.07) but our ability to draw any meaningful causal
inferences is limited by these potential biases.
CAPITAL-AMI
In this study, 170 STEMI patients treated with fibrinoly-
sis were randomized to routine immediate PCI or fibri-
nolysis alone with rescue or deferred PCI as clinically
indicated[20]. Cardiac catheterization was performed in-
hospital in 67% of the patients in the fibrinolysis-alone
group, with 50% of patients in this group undergoing
PCI (including 14% rescue PCI). The primary composite
endpoint of death, reinfarction, recurrent unstable
ischemia, or stroke at 6 months was reduced with the
pharmacoinvasive strategy from 24.4% to 11.6% (relative
risk: 0.48; 95% CI: 0.24-0.96; p = 0.04). This difference
w a sd r i v e nb yar e d u c t i o ni nt h er a t eo fr e c u r r e n t
unstable ischemia that included reinfarction (20.7% vs.
8.1%; relative risk 0.39; 95% CI: 0.17-0.90; p = 0.03).
There was no difference in death, stroke, heart failure/
cardiogenic shock, left ventricular ejection fraction, or
treadmill exercise duration between the 2 groups. Inter-
estingly, there was also no improvement in ST-segment
resolution, an important predictor of mortality[21], with
routine immediate PCI[22]. Again in this relatively
small study, unbalanced use of clopidogrel (91% in the
pharmacoinvasive arm compared with 57% in the fibri-
nolysis-alone arm) may well have confounded the differ-
ence in recurrent unstable ischemia between the 2
approaches.
LEIPZIG Study
This RCT compared immediate versus delayed PCI in
164 STEMI patients treated with fibrinolysis (half-dose
reteplase) plus abciximab[23]. The composite secondary
clinical endpoint of death, reinfarction, major bleeding,
and stroke at 6 months was not significantly reduced
with immediate PCI (15% versus 25%; relative risk: 0.57;
95% CI: 0.28-1.13; p = 0.1), although the study did have
limited power to attain this endpoint. As with SIAM-3,
the Leipzig study examined the timing of PCI rather
than the benefits of a pharmacoinvasive versus ische-
mia-guided approach. Timing of the introduction of clo-
pidogrel was not specified but likely was postponed in
the delayed PCI group, potentially confounding the
assessment of outcome in the 2 groups. Finally, the
combination of half-dose fibrinolysis and platelet glyco-
protein inhibition has not been found to be more effica-
cious than standard fibrinolysis and also results in more
bleeding complications, particularly in older patients
[24]. Thus, the findings of this small study are not read-
ily pertinent to an examination of the benefit of a phar-
macoinvasive approach versus a selective invasive
approach based on risk and clinical evolution in patients
with STEMI.
Table 2 Thirty-day outcomes of randomized clinical trials comparing an invasive treatment strategy to a delayed inva-
sive or ischemia-guided approach among STEMI patients treated with fibrinolysis (Continued)
Recurrent Ischemia 1/536 11/522 0.09 (0.01, 0.68) 0.003
Death/Reinfarction/Recurrent Ischemia 39/536 58/522 0.65 (0.44, 0.96) 0.03
New or Worsening CHF 16/536 29/522 0.54 (0.30, 0.98) 0.04
Cardiogenic Shock 24/536 16/522 1.46 (0.79, 2.72) 0.23
NORDISTEMI[28] Death/Reinfarction/Stroke/New Ischemia 14/134 28/132 0.49 (0.27, 0.89)
‡ 0.02
‡
Death/Reinfarction/Stroke 6/134 13/132 0.45 (0.18, 1.16)
‡ 0.09
‡
Death 3/134 3/132 0.99 (0.20, 4.79)
‡ 1.00
‡
Reinfarction 2/134 7/132 0.28 (0.06, 1.33)
‡ 0.10
‡
Stroke 3/134 5/132 0.59 (0.14, 2.42)
‡ 0.50
‡
Recurrent Ischemia 8/134 16/132 0.49 (0.22, 1.11)
‡ 0.08
‡
Abbreviations: CHF: congestive heart failure; CI: confidence interval; MI: myocardial infarction; TLR: target lesion revascularization.
*Denotes primary endpoint of the trial. † Data are based on the 163 patients who met the secondary inclusion criteria rather than the 197 who were
randomized.
†† Data are based on the 197 patients who were randomized. ‡ Calculated using data presented in the original manuscript.
¥ Denotes p-value from
log-rank test.
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Page 6 of 15Table 3 Six-and 12-month outcomes of randomized clinical trials comparing an invasive treatment strategy to a
delayed invasive or ischemia-guided approach among STEMI patients treated with fibrinolysis
Study Follow-
Up
Outcome Risk in Invasive
Group
(n/N)
Risk in Selective
Group
(n/N)
Relative Risk
(95% CI)
p-value
PRAGUE[17] 12
Months
Death/Non-Fatal Reinfarction 18/100 30/99 0.59 (0.36, 0.99) 0.04
‡
Death 12/100 18/99 0.66 (0.34, 1.30) 0.22
‡
Non-Fatal Reinfarction 6/100 12/99 0.50 (0.19, 1.27) 0.13
‡
SIAM-3[18] 6
Months
†
CABG 6/82 6/81 0.99 (0.33, 2.94)
‡ 0.609
TLR 16/82 19/81 0.83 (0.46, 1.50)
‡ 0.336
Ischemic Events 4/82 23/81 0.17 (0.06, 0.47)
‡ 0.001
Reinfarction 2/82 2/81 0.99 (0.14, 6.84)
‡ 0.685
Death 4/82 9/81 0.44 (0.14, 1.37)
‡ 0.119
Death/Reinfarction 6/82 11/81 0.54 (0.21, 1.39)
‡ 0.146
Death/Reinfarction/TLR 20/82 29/81 0.68 (0.42, 1.10)
‡ 0.078
Death/Reinfarction/TLR/Ischemic Events* 21/82 41/81 0.51 (0.33, 0.78)
‡ 0.001
6
Months
††
CABG 12/94 19/103 0.69 (0.36, 1.35)
‡ 0.185
TLR 22/94 31/103 0.78 (0.49, 1.24)
‡ 0.185
Ischemic Events 7/94 28/103 0.27 (0.13, 0.60)
‡ 0.001
Reinfarction 3/94 3/103 1.10 (0.23, 5.30)
‡ 0.614
Death 4/94 9/103 0.49 (0.16, 1.53)
‡ 0.164
Death/Reinfarction 7/94 12/103 0.64 (0.27, 1.56)
‡ 0.225
Death/Reinfarction/TLR 26/94 41/103 0.69 (0.46, 1.04)
‡ 0.049
Death/Reinfarction/TLR/Ischemic Events 28/94 55/103 0.56 (0.39, 0.80)
‡ 0.001
GRACIA-1[19] 12
Months
Death 9/248 16/251 0.55 (0.22, 1.36) 0.16
Non-Fatal Reinfarction 9/248 15/251 0.60 (0.27, 1.36) 0.22
Death/Non-Fatal Reinfarction 17/248 29/251 0.59 (0.33, 1.05) 0.07
Revascularization 9/248 30/251 0.30 (0.15, 0.62) 0.001
Readmission due to Ischemia 37/248 62/251 0.60 (0.42, 0.87) 0.006
Death/Non-Fatal Reinfarction/
Revascularization*
23/248 51/251 0.44 (0.28, 0.70) 0.0008
CAPITAL-AMI
[20]
6
Months
Death/Recurrent MI/Recurrent Unstable
Ischemia, Stroke*
10/86 20/84 0.48 (0.24, 0.96) 0.04
Death 3/86 3/84 0.95 (0.20, 4.59) 1.00
Reinfarction 5/86 12/84 0.40 (0.15, 1.08) 0.07
Recurrent Unstable Ischemia 7/86 17/84 0.39 (0.17, 0.90) 0.03
Stroke 1/86 1/84 0.95 (0.60, 14.99) 1.00
Death/Reinfarction/Stroke 8/86 15/84 0.51 (0.23, 1.14) 0.12
Leipzig[23] 6
Months
Death 5/82 6/82 0.83 (0.22, 2.99) 0.68
¥
Death/Reinfarction/Stroke/Major Bleeding 12/82 21/82 0.57 (0.28, 1.13) 0.10
¥
TRANSFER AMI
[27]
6
Months
Death 30/528 23/511 1.27 (0.77, 2.23) 0.39
Reinfarction 21/528 33/511 0.60 (0.34, 1.05) 0.07
Death/Reinfarction 47/528 54/511 0.83 (0.55, 1.25) 0.36
NORDISTEMI
[28]
12
Months
Death/Reinfarction/Stroke/New Ischemia* 28/134 36/132 0.77 (0.50, 1.18)
‡ 0.22
‡
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This trial randomized 304 patients with STEMI to fibri-
nolysis alone (n = 100), fibrinolysis plus transfer for PCI
within 24 hours (n = 104), or primary PCI (n = 100)
[25]. In-hospital revascularization was undertaken in
60% of the fibrinolysis-alone patients (rescue PCI in
14%). There was no significant difference in the 30-day
primary composite efficacy endpoint (death, reinfarction,
heart failure, cardiogenic shock, refractory ischemia, and
major ventricular arrhythmias) that occurred in 24% of
the pharmacoinvasive group and in 25% of the fibrinoly-
sis alone group (relative risk 0.96; 95% CI: 0.59-1.56; p =
0.87). A reduced composite endpoint of death and rein-
farction was not significant between the two groups
(6.7% in the pharmacoinvasive versus 13.0% in the fibri-
nolysis alone group), although the power to detect dif-
ferences was limited in this small study. No information
was available about the nature and timing of the small
number of reinfarctions but systematic use of clopido-
grel in the pharmacoinvasive group and its likely less
frequent use in the fibrinolysis group before any PCI as
well as a higher threshold for defining myocardial
infarction if it was related to PCI are factors that likely
attenuate the small difference in reinfarction noted in
the 2 groups.
CARESS-AMI
This study randomized 600 patients, aged ≤75 years, to
a pharmacoinvasive approach or standard ischemia-
guided management (including rescue PCI) after receiv-
ing half-dose reteplase and abciximab[26]. In the latter
group, in-hospital angiography was performed in 36%
and PCI in 30%. The primary outcome was a composite
endpoint of death, reinfarction, and refractory ischemia
at 30 days and occurred in 13 patients (4.4%) in the
pharmacoinvasive group versus 32 patients (10.7%) in
the standard care/rescue group (relative risk 0.41; 95%
CI 0.22-0.77; p = 0.005). This endpoint was driven by
reduced refractory ischemia that occurred at 30 days in
only one patient (0.3%) in the pharmacoinvasive group
versus 12 patients (4.3%) in the standard care/rescue
group (p = 0.003). The corresponding occurrences of
death and reinfarction at 30 days were 3.0% vs. 4.7%
(relative risk 0.65; 95% CI: 0.29-1.48; p = 0.4) and 1.3%
vs. 2.0% (relative risk 0.68; 95% CI: 0.19-2.36; p = 0.75),
respectively. Clear and equal application of diagnostic
tests to both groups following randomization was not
specified, leaving the possibility of a diagnostic bias for
ischemia detection in a necessarily unblinded study.
TRANSFER AMI
In this study, 528 patients were randomized to PCI per-
formed within 4 hours after fibrinolysis (early pharma-
coinvasive group) and 511 patients were randomized to
‘standard’ treatment (defined as rescue PCI performed
for clinically failed reperfusion and a recommendation
that cardiac catheterization be performed in all patients
within 2 weeks)[27]. The use of cardiac catheterization
in the standard treatment group was consequently very
high (89%). This was therefore essentially a trial of the
timing of PCI after fibrinolysis that compared an early
to a later pharmacoinvasive approach. The composite
endpoint of 30-day death, reinfarction, congestive heart
failure, severe recurrent ischemia, and shock occurred in
11.0% of the immediate PCI arm and 17.2% of the stan-
dard arm (relative risk 0.64; 95% CI: 0.47-0.87; p =
0.004). The difference in the 2 groups was again driven
by recurrent ischemia (0.2% vs.2 . 1 % ;r e l a t i v er i s k0 . 0 9 ;
95% CI: 0.01-0.68; p = 0.003) and reinfarction (3.4% vs.
5.7%; relative risk 0.57; 95% CI: 0.33-1.04; p = 0.06). At
6 months, there was no significant difference in death
or reinfarction between the 2 groups (8.9% in the rou-
tine early group vs 10.6% in the standard group; relative
risk 0.83; 95% CI: 0.55-1.25; p = 0.36). Again, the use of
clopidogrel was not equal in the 2 arms; although rela-
tively high in the standard treatment arm (69% within
the first 6 h), it was lower than in the routine early PCI
group (89%).
NORDISTEMI
This RCT compared a strategy of immediate transfer for
PCI with an ischemia-guided approach after fibrinolysis
(pre-hospital in 57%) in 266 patients situated too far
away for timely primary PCI[28]. In the immediate
Table 3 Six-and 12-month outcomes of randomized clinical trials comparing an invasive treatment strategy to a
delayed invasive or ischemia-guided approach among STEMI patients treated with fibrinolysis (Continued)
Death/Reinfarction/Stroke 8/134 21/132 0.38 (0.17, 0.82)
‡ 0.008
‡
Death 3/134 4/132 0.74 (0.17, 3.24)
‡ 0.72
‡
Reinfarction 4/134 12/132 0.33 (0.11, 0.99)
‡ 0.04
‡
Stroke 3/134 7/132 0.42 (0.11, 1.60)
‡ 0.22
‡
Recurrent Ischemia 20/134 20/132 0.99 (0.56, 1.74)
‡ 0.96
‡
Abbreviations: CHF: congestive heart failure; CI: confidence interval; MI: myocardial infarction; TLR: target lesion revascularization. * Denotes primary endpoint of
the trial. † Data are based on the 163 patients who met the secondary inclusion criteria rather than the 197 who were randomized.
†† Data are based on the 197
patients who were randomized. ‡ Calculated using data presented in the original manuscript.
¥ Denotes p-value from log-rank test.
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Page 8 of 15Figure 2 Thirty-day outcomes of randomized clinical trials comparing an invasive treatment strategy to a delayed invasive or
ischemia-guided approach among STEMI patients treated with fibrinolysis. Abbreviations: CHF = Congestive Heart Failure; TLR = Target
Lesion Revascularization. *New or worsening CHF. **Non-fatal reinfarction. ‡ Recurrent unstable ischemia. ‡‡ Refractory ischemia. † Data are
based on the 163 patients who met the secondary inclusion criteria rather than the 197 who were randomized. †† Data are based on the 197
patients who were randomized.
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Page 9 of 15transfer group, the median time from receiving fibrino-
lysis to arrival at the catheterization laboratory was 130
m i na n dP C Iw a sp e r f o r m e di n8 9 % .I nt h ei s c h e m i a -
guided management arm, 27% underwent rescue PCI
and 93% of the remainder had cardiac catheterization in
the following days (at a median time of 5.5 days for the
group as a whole). PCI was performed in 71% and cor-
onary bypass surgery in 12% of this ‘conservative’ group.
The terms ‘ischemia-guided management’ and ‘conserva-
tive’ used by the authors to characterize this latter group
are somewhat misnomers because nearly all these
patients underwent invasive management sooner or
later. The primary endpoint of death, reinfarction,
stroke, and recurrent ischemia at 12 months was not
significantly different between the 2 strategies (21% in
early invasive group vs. 27% in ‘conservative group’; rela-
tive risk: 0.77; 95% CI: 0.50-1.18; p = 0.22). The authors
h i g h l i g h tt h ef i n d i n gt h a ta ne n d p o i n tr e s t r i c t e dt o
death, stroke, and reinfarction at 12 months was signifi-
cantly reduced in the immediate pharmacoinvasive
group (6% vs 16%, relative risk: 0.38; 95% CI: 0.17-0.82;
p = 0.008). The pertinence of this finding is difficult to
gauge because between 30 days and 12 months, there
was a marked increase in recurrent ischemia in the
Figure 3 Six-month outcomes of randomized clinical trials comparing an invasive treatment strategy to a delayed invasive or
ischemia-guided approach among STEMI patients treated with fibrinolysis. Abbreviations: CABG = Coronary Artery Bypass Graft Surgery;
TLR = Target Lesion Revascularization. ‡ Recurrent unstable ischemia. † Data are based on the 163 patients who met the secondary inclusion
criteria rather than the 197 who were randomized. †† Data are based on the 197 patients who were randomized.
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Page 10 of 15immediate pharmacoinvasive group while in the same
period, there was an increase in stroke and reinfarction
in the ‘conservative’ arm. Beyond the play of chance, it
is unclear why these directionally discordant vascular
event rates should have occurred within this later time
frame.
Discussion
This complete and detailed review of the RCTs that
evaluated routine invasive management against a com-
parator strategy following fibrinolysis in patients with
STEMI has found important methodological limitations
to performing a meta-analysis of the available evidence.
Importantly, the comparator to routine invasive manage-
ment has varied widely from systematic but deferred
invasive management to large differences in the propor-
tion of patients in the comparator arm who underwent
invasive management. Additionally, several potential
biases were identified that might confound the findings
of the individual RCTs. Thus, this systematic review
concludes that definitive RCT evidence in favor of rou-
tine invasive management following fibrinolysis in
patients with STEMI is presently lacking.
Although primary PCI has tended to become the
favored reperfusion therapy wherever it is readily avail-
able, a substantial proportion of patients with STEMI
still receive fibrinolysis. Since the widespread introduc-
tion of fibrinolysis 3 decades ago, a recurring clinical
question has been: Should all patients be subsequently
routinely referred for invasive management (coronary
angiography and anatomically driven revascularization)?
Or, following fibrinolysis, should invasive management
be more selective or ‘ischemia-guided’, based on higher
risk characteristics such as recurrent or refractory
Figure 4 One-year outcomes of randomized clinical trials comparing an invasive treatment strategy to a delayed invasive or ischemia-
guided approach among STEMI patients treated with fibrinolysis. **Non-fatal reinfarction. ***Readmission due to ischemia.
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Page 11 of 15ischemia and non-invasive risk stratification such as an
exercise test or myocardial imaging suggesting the pre-
sence of a significant ischemic substrate? A secondary
question for clinicians favoring routine invasive inter-
vention after fibrinolysis has been its timing: earlier or
later? The issue at stake is important both clinically and
from the perspective of allocation of costly technological
infrastructure. Should treatment of STEMI systemati-
cally engage the resources of tertiary cardiac care or can
clinicians exercise sufficient clinical acumen to selec-
tively reserve invasive management to identifiable high-
risk patients without prejudice to overall patient welfare?
Guidelines have attempted to address these questions
but the strength of evidence on which these recommen-
dations are based has not been critically reviewed.
In the more contemporary era, fueled by post-hoc
analysis of clinical trials[29,30] and interpretation of reg-
istry findings[31] and RCTs examining either this ques-
tion or the secondary question of the timing of invasive
management, patients are increasingly routinely referred,
and ever earlier, for invasive management after fibrinoly-
sis. A meta-analysis by Wijeysundera et al. examined 5
contemporary studies purporting to compare a
pharmacoinvasive approach versus ‘ischemia-guided
management’[32]. In the present review, we have added
4 additional RCTs, 2 that used a combination of a fibri-
nolytic and a platelet 2b/3a antagonist[23,26] plus 2
other studies published since this meta-analysis[27,28].
Like the meta-analysis by Wijeysundera et al., all 9
RCTs suggest a benefit, albeit relatively small in absolute
terms, from a strategy of routine and ever earlier inva-
sive management following fibrinolysis. Consequently, a
similar benefit was found in 2 very recent meta-analyses
both of which compared early/immediate routine inva-
sive management with ‘standard therapy’[33] or ‘am o r e
conservative strategy’[34] that was without distinction
either deferred routine invasive management or an
ischemia-guided strategy.
However, given the diverse and non-standardized
study interventions, routine invasive versus a fluctuating
standard care approach (with invasive rates varying from
7% to 67%) or simply an early versus deferred universal
invasive strategy (in which there was no contrast in
intervention rates only in timing), we believe a quantita-
tive meta-analysis is inappropriate. We have therefore
chosen instead to qualitatively review the RCTs
Figure 5 Thirty-day composite outcomes of death/reinfarction and death/reinfarction/stroke reported in randomized clinical trials
comparing an invasive treatment strategy to a delayed invasive or ischemia-guided approach among STEMI patients treated with
fibrinolysis. †Data are based on the 163 patients who met the secondary inclusion criteria rather than the 197 who were randomized.
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Page 12 of 15individually. Other difficulties in determining if these
RCTs establish a causal benefit of a pharmacoinvasive
approach include: use of a sub-optimal fibrinolytic agent
[16]; confounding due to the asymmetric use of a sec-
ond anti-platelet agent (usually clopidogrel) known to
significantly reduce recurrent ischemia and reinfarction
[18-20,25,27]; preponderance of the ‘soft’ outcome of
recurrent ischemia in the combined primary endpoint in
unblinded studies exposing to potential ascertainment
bias [18-20,26,27]; information bias when only the num-
ber of follow-up invasive procedures are tallied and
those occurring early as part of the study design in the
pharmacoinvasive arm are not counted[19]; and misclas-
sification bias whereby, the diagnosis of myocardial
infarction differs between the invasive and standard
arms (generally, a higher cardiac enzyme threshold
required for recurrent myocardial infarction following
PCI, although the latter does appear to have a better
prognosis than a spontaneously occurring myocardial
infarction[35]).
Consequently, while these RCTs are regularly cited to
support a pharmacoinvasive approach, this systematic
review suggests that these potential biases and heteroge-
neity in the evidence makes definitive conclusions hazar-
dous. Importantly, meta-analysis with a summary effect
size and corresponding 95% CI represents only the ran-
dom error and not the systematic errors associated with
these potential biases.
Is there an optimal rate of invasive management
following fibrinolysis?
The RCTs have evaluated routine versus selective inva-
sive management with a wide variation in the latter, or
have compared only the timing of a pharmacoinvasive
approach. Because of this evidence base and because
clinicians increasingly favor the pharmacoinvasive
approach, the optimal rate of coronary angiography and
revascularization following fibrinolysis in STEMI
patients remains unclear. This question assumes that
clinical judgment can be sufficiently reliable that the
patients who will benefit from invasive management will
be accurately identified and unnecessary procedures can
be avoided in those who will not derive benefit. Obser-
vations from registries and clinical studies do suggest
the presence of a threshold effect[36-39]. Above a cer-
tain rate of invasive recourse, little or no additional
benefit is noted. Below this rate, outcomes analysis
suggests suboptimal treatment, placing patients at risk.
A systematic review in 2001 concluded that rates of
coronary angiography and revascularization following
myocardial infarction in excess of 30% and 20%,
respectively, might not confer additional benefit in pre-
venting death and reinfarction[40]. Consistent with
this, more recently, a substudy of the multinational
fibrinolytic GUSTO-V trial examined the relationship
between early revascularization (within 7 days of
STEMI) and one-year mortality in 13,451 patients.
These data suggested an optimal rate of early revascu-
larization of 20-30%[38]. In the studies included in the
present review, only GRACIA-1 and CARESS-AMI had
rates of angiography/PCI within this range in their
ischemia-guided arms[19,26]. This evidence base is
clearly insufficient to conclude whether a systematic
pharmacoinvasive strategy is superior to an appropri-
ately selective ischemia-guided approach.
Conclusion
Ever earlier routine coronary angiography and anatomy-
driven PCI in STEMI patients treated with fibrinolysis is
being strongly promoted by reviews, meta-analyses, sup-
porting editorials, opinion-leaders, and guidelines
[5,9,31-34,41-45]. Given these numerous publications, it
is not surprising that this aggressive approach to clinical
management of STEMI patients has become the zeitgeist
of acute coronary care. Yet our critical and systematic
review of available data from RCTs suggests that evi-
dence to support this ‘pharmacoinvasive’ approach ver-
sus a truly selective ischemia-guided approach is more
byzantine than conclusive. We believe guidelines should
reflect this uncertainty rather than endorse the prevail-
ing penchant[46]. While awaiting definitive evidence
regarding which strategy is superior, the more attractive
challenge may lie in not treating all patients in the same
aggressive manner but in matching clinical management
to the unique profiles of individual patients, their base-
line risks, and the specific dynamics of their clinical evo-
lution. Thus, it seems reasonable that following
fibrinolysis, patients who evolve well and do not show
low-threshold or important ischemia on non-invasive
risk stratification like an exercise test can be considered
at low risk and can be managed conservatively while
higher-risk patients can be treated more aggressively.
This approach is at the same time consistent with
rational use of expensive resources and ultimately the
only sensible way to contain runaway healthcare costs in
acute coronary disease without adversely affecting
patient outcomes.
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